MX2020013236A - Acido ribonucleico (arn) circular para traduccion en celulas eucariotas. - Google Patents

Acido ribonucleico (arn) circular para traduccion en celulas eucariotas.

Info

Publication number
MX2020013236A
MX2020013236A MX2020013236A MX2020013236A MX2020013236A MX 2020013236 A MX2020013236 A MX 2020013236A MX 2020013236 A MX2020013236 A MX 2020013236A MX 2020013236 A MX2020013236 A MX 2020013236A MX 2020013236 A MX2020013236 A MX 2020013236A
Authority
MX
Mexico
Prior art keywords
vector
spacer sequence
circular rna
disclosed
eukaryotic cells
Prior art date
Application number
MX2020013236A
Other languages
English (en)
Inventor
Daniel G Anderson
Robert Alexander Wesselhoeft
Piotr S Kowalski
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2020013236A publication Critical patent/MX2020013236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/859—Animal models comprising reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/202—Pseudochromosomes, minichrosomosomes of bacteriophage origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/55—Vectors comprising a special translation-regulating system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos y constructos para diseñar ARN circular; se describe un vector para formar ARN circular, dicho vector comprende los siguientes elementos conectados operativamente entre sí y dispuestos en la siguiente secuencia: a.) un brazo de homología 5 en 5', b.) un fragmento de intrón de grupo I en 3' que contiene un dinucleótido de sitio de empalme en 3', c.) opcionalmente, una secuencia espaciadora en 5', d.) una región codificante o no codificante de proteína, e.) opcionalmente, una secuencia espaciadora en 3', f.) un fragmento de intrón de Grupo I en 5' que contiene un dinucleótido de sitio de empalme en 5', y g.) un brazo de homología en 3', dicho vector permite la producción de un ARN circular que es traducible o biológicamente activo dentro de células eucariotas; en otra modalidad, el vector puede comprender la secuencia espaciadora en 5', pero no la secuencia espaciadora en 3' en incluso otra modalidad, el vector puede comprender la secuencia espaciadora en 3', pero no la secuencia espaciadora en 5'; también se describe un método para la purificación del ARN circular producido por el vector y el uso de modificaciones del nucleósido en el ARN circular producido por el vector.
MX2020013236A 2018-06-06 2019-06-05 Acido ribonucleico (arn) circular para traduccion en celulas eucariotas. MX2020013236A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862681617P 2018-06-06 2018-06-06
US201962791028P 2019-01-10 2019-01-10
US201962851548P 2019-05-22 2019-05-22
PCT/US2019/035531 WO2019236673A1 (en) 2018-06-06 2019-06-05 Circular rna for translation in eukaryotic cells

Publications (1)

Publication Number Publication Date
MX2020013236A true MX2020013236A (es) 2021-02-22

Family

ID=67253953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013236A MX2020013236A (es) 2018-06-06 2019-06-05 Acido ribonucleico (arn) circular para traduccion en celulas eucariotas.

Country Status (12)

Country Link
US (8) US11981909B2 (es)
EP (1) EP3801639A1 (es)
JP (2) JP2021526792A (es)
KR (1) KR20210018323A (es)
CN (2) CN118256490A (es)
AU (2) AU2019280583B2 (es)
BR (1) BR112020024292A2 (es)
CA (1) CA3100276A1 (es)
IL (2) IL319091A (es)
MX (1) MX2020013236A (es)
SG (1) SG11202011162RA (es)
WO (1) WO2019236673A1 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200127152A (ko) 2017-12-15 2020-11-10 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도
BR112020024292A2 (pt) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
US20220296729A1 (en) * 2019-06-19 2022-09-22 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
WO2021113777A2 (en) * 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Circular rna compositions and methods
CN111297884B (zh) * 2020-04-02 2021-03-30 中国农业科学院蜜蜂研究所 腺苷在蜜蜂病毒感染防治中的应用
JP2023525270A (ja) * 2020-05-08 2023-06-15 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
AU2021297340A1 (en) * 2020-06-25 2023-01-19 The Board Of Trustees Of The Leland Stanford Junior University Genetic elements driving circular RNA translation and methods of use
CN115667317B (zh) * 2020-06-30 2024-08-30 南京驯鹿生物技术股份有限公司 全人源的靶向cd19和cd22双特异抗原嵌合受体及其应用
IL299261A (en) 2020-07-01 2023-02-01 Elevatebio Tech Inc Compositions and methods for cellular reprogramming using circular rna
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
WO2022116528A1 (zh) * 2020-12-04 2022-06-09 苏州科锐迈德生物医药科技有限公司 环状rna、包含环状rna的疫苗及用于检测新型冠状病毒中和抗体的试剂盒
CN112481289B (zh) 2020-12-04 2023-06-27 苏州科锐迈德生物医药科技有限公司 一种转录环状rna的重组核酸分子及其在蛋白表达中的应用
CN112725378B (zh) * 2021-01-17 2022-10-04 昆明医科大学 一种人工改造的akt3环状rna及其在新冠疫苗中的应用
CN112877360B (zh) * 2021-02-07 2023-06-27 中山大学附属第一医院 一种检测ires活性的环rna荧光素酶报告质粒构建方法
WO2022173730A1 (en) * 2021-02-09 2022-08-18 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
EP4116421A4 (en) * 2021-03-10 2024-08-14 Rznomics Inc. Self-circularized rna structure
CN112941020B (zh) * 2021-04-06 2023-03-10 广东海洋大学 一种鸡环状rna在促进成肌细胞的增殖的应用
CN113278635B (zh) * 2021-05-25 2023-05-19 广州艾基生物技术有限公司 一种促进环状rna成环的序列组合及其应用
CN115404240A (zh) * 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
CN115433733A (zh) * 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN113344272B (zh) * 2021-06-08 2022-06-21 汕头大学 一种基于机器学习的circRNA与miRNA、RBP相互作用关系的预测方法
TW202317767A (zh) * 2021-06-10 2023-05-01 美商歐納醫療公司 環狀rna組合物及方法
WO2023009568A1 (en) 2021-07-27 2023-02-02 Flagship Pioneering Innovations Vi, Llc Devices systems and methods for processing
JP2024531486A (ja) * 2021-08-27 2024-08-29 北京大学 環状ｒｎａを調製するための構築物及び方法
WO2023038433A1 (ko) * 2021-09-07 2023-03-16 진원생명과학 주식회사 원형 rna 및 그의 이용
CN118234867A (zh) * 2021-09-17 2024-06-21 旗舰创业创新六公司 用于产生环状多核糖核苷酸的组合物和方法
CA3181628A1 (en) * 2021-11-16 2023-05-16 Martin Williams Circular rna platforms, uses theroeof, and their manufacturing processes from engineered dna
US20240401024A1 (en) 2021-12-17 2024-12-05 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
US20250051816A1 (en) * 2021-12-21 2025-02-13 Peking University Single-pot methods for producing circular rnas
EP4453201A1 (en) 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
JP2025500358A (ja) 2021-12-23 2025-01-09 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 抗膜融合ポリペプチドをコードする環状ポリリボヌクレオチド
WO2023143538A1 (zh) * 2022-01-28 2023-08-03 北京辑因医疗科技有限公司 基于leaper技术治疗mpsi的方法和组合物
CN117417937A (zh) * 2022-01-31 2024-01-19 奥明(杭州)生物医药有限公司 一种环状rna分子及应用
CN114504658B (zh) * 2022-02-25 2023-07-21 上海大学 一种治疗阿霉素诱导的心脏毒性损伤的药物及应用
CN114507691A (zh) * 2022-03-02 2022-05-17 深圳市瑞吉生物科技有限公司 一种用于制备环状rna的载体及其应用
CN114574483B (zh) 2022-03-02 2024-05-10 苏州科锐迈德生物医药科技有限公司 基于翻译起始元件点突变的重组核酸分子及其在制备环状rna中的应用
CN117965543A (zh) 2022-03-02 2024-05-03 苏州科锐迈德生物医药科技有限公司 一种重组核酸分子及其在制备环状rna中的应用
CN114480499A (zh) * 2022-03-04 2022-05-13 中国人民解放军陆军军医大学 环状RNA分子表达元件以及环状RNA分子的表达载体circEXPRO
CN114875053A (zh) * 2022-03-11 2022-08-09 杭州师范大学 一种高效稳定环状rna的构建方法及其产品
JP2025509106A (ja) 2022-03-21 2025-04-11 バイオ アドヴェンチャー カンパニー リミテッド タンパク質発現を増強するための、配列内リボソーム進入部位（ＩＲＥＳ）、プラスミドベクター及び環状ｍＲＮＡ
WO2023195930A2 (en) * 2022-04-06 2023-10-12 Agency For Science, Technology And Research Vector for generating a circular rna
WO2023222114A1 (en) * 2022-05-20 2023-11-23 Innoforce Pharmaceuticals Methods of making circular rna
KR20250019772A (ko) 2022-05-25 2025-02-11 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
KR20250017231A (ko) 2022-05-25 2025-02-04 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 면역 반응을 조절하기 위한 조성물 및 방법
EP4532768A2 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulating circulating factors
AU2023277636A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
EP4532767A2 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulating cytokines
EP4539858A1 (en) 2022-06-17 2025-04-23 Sanofi Pasteur Inc. Compositions and methods for circular rna affinity purification
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024010028A1 (ja) * 2022-07-06 2024-01-11 国立大学法人京都大学 環状ｒｎａ分子及びこれを用いた翻訳制御方法、翻訳活性化システム、並びに医薬組成物
CN115786374B (zh) 2022-07-06 2023-10-13 广州吉赛生物科技股份有限公司 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法
CN119768517A (zh) * 2022-07-08 2025-04-04 上海环码生物医药有限公司 用于纯化环状核酸的方法和系统
WO2024030456A2 (en) * 2022-08-01 2024-02-08 Esperovax Inc. Targeted rna circularization
WO2024054047A1 (ko) * 2022-09-06 2024-03-14 알지노믹스 주식회사 자가 환형화 rna 구조체
WO2024054048A1 (ko) * 2022-09-06 2024-03-14 알지노믹스 주식회사 자가 환형화 rna 구조체
US12247202B2 (en) 2022-09-10 2025-03-11 Exclcirc (Suzhou) Biomedical Co., Ltd. Circular RNAS and preparation methods thereof
US20250002959A1 (en) * 2022-09-13 2025-01-02 Suzhou Abogen Biosciences Co., Ltd. One-Step Method for Synthesis of Circular RNA
TW202434728A (zh) * 2022-11-08 2024-09-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸的組成物和方法
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions
WO2024121339A1 (en) * 2022-12-07 2024-06-13 Circio Ab Circrna expression construct
WO2024129779A1 (en) * 2022-12-12 2024-06-20 Modernatx, Inc. Internal ribosome entry sites for improved polynucleotide translation
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024131232A1 (zh) * 2022-12-20 2024-06-27 杭州明德生物医药技术有限公司 环状rna分离和纯化方法
WO2024137392A1 (en) * 2022-12-22 2024-06-27 Genscript Usa Inc. Method of preparing self-circularized rna
KR102584714B1 (ko) * 2022-12-28 2023-10-10 라이보텍(주) 덤벨 구조를 이용한 원형 rna 제조 방법
TW202426640A (zh) * 2022-12-29 2024-07-01 大陸商蘇州艾博生物科技有限公司 Rna環化
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
CN118360300A (zh) * 2023-01-10 2024-07-19 优环(苏州)生物医药科技有限公司 一种表达尿酸氧化酶的环状rna、制备方法及应用
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
CN116286916A (zh) * 2023-02-24 2023-06-23 北京大学人民医院 一种改良的i型内含子核酶序列用于构建环状rna的方法及应用
WO2024192420A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2024192277A2 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024193634A1 (en) * 2023-03-21 2024-09-26 Ribox Therapeutics Hk Limited Circular rna and preparation method thereof
CN117070564B (zh) * 2023-03-30 2024-05-10 安可来(重庆)生物医药科技有限公司 一种用于合成环形rna的质粒及其构建方法与一种环形rna及其体外合成方法
CN118773251A (zh) * 2023-03-31 2024-10-15 深圳菁童生命科学有限公司 一种重组核酸载体及其在制备环状rna分子中的用途
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof
WO2024240226A1 (en) * 2023-05-23 2024-11-28 Peking University Methods of forming circularized rna
WO2024240260A1 (zh) * 2023-05-24 2024-11-28 南京金斯瑞生物科技有限公司 用于制备环状rna的载体和方法
WO2024254546A2 (en) * 2023-06-08 2024-12-12 Cornell University Virus-like particles comprising circular mrna expression systems and methods of use thereof
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
CN119265241A (zh) 2023-06-30 2025-01-07 深圳菁童生命科学有限公司 一种无相分离转录因子介导启始阶段重编程使细胞年轻化的方法
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
CN116694666A (zh) * 2023-07-07 2023-09-05 浙江大学 一种环形rna高效表达载体及其应用
CN116732039B (zh) * 2023-08-03 2023-11-14 呈诺再生医学科技(北京)有限公司 一种促进rna序列在细胞内直接环化翻译的序列组合及其应用
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025052303A1 (en) * 2023-09-08 2025-03-13 Beigene Switzerland Gmbh Circular rna and preparation methods thereof
WO2025072615A1 (en) * 2023-09-29 2025-04-03 Orbital Therapeutics, Inc. Improved methods of making rna by splinted ligation and compositions thereof
WO2025076037A1 (en) * 2023-10-02 2025-04-10 University Of Massachusetts Circular rna vectors comprising modified nucleotides
CN117051043B (zh) * 2023-10-11 2024-01-30 圆因(北京)生物科技有限公司 一种基于环状rna编码耐甲氧西林金黄色葡萄球菌内溶素及其应用
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
CN117821508B (zh) * 2023-10-18 2025-04-11 中山大学中山眼科中心 一种编码NGF蛋白的工程化circRNA、药物组合物及其制备方法和应用
WO2025085695A1 (en) * 2023-10-18 2025-04-24 Trustees Of Dartmouth College Lipid nanoparticle formulations for delivery of nucleic acids to primary human b-cells
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
CN117568337B (zh) * 2023-11-16 2025-04-22 南京鸿明生物科技有限公司 一种基于人源tRNA的自环化RNA
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025111280A1 (en) * 2023-11-20 2025-05-30 Strand Therapeutics Inc. Circular rna synthesis
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
CN117431258B (zh) * 2023-12-20 2024-06-28 上海元戊医学技术有限公司 使用含有Tet1基因的重编程因子诱导人体细胞重编程的方法
CN117947028A (zh) * 2023-12-29 2024-04-30 北京衡昱生物科技有限公司 Ires-w3-31序列及其应用
CN117904198B (zh) * 2024-01-22 2025-03-18 蓝宝泰(山西)生物医药有限公司 一种利用嵌合pie系统体外制备环状rna的方法与应用
CN118028340B (zh) * 2024-01-31 2025-04-29 北京悦康科创医药科技股份有限公司 一种用于环状rna表达的核酸构建体及其在蛋白表达中的应用
CN118291452B (zh) * 2024-02-28 2025-03-14 山西高等创新研究院 一种基于i型内含子核酶体外制备环状rna的系统及其应用
CN118374525B (zh) * 2024-04-22 2025-02-25 广州派真生物技术有限公司 一种环状rna转录载体及其制备方法和应用
CN118652889B (zh) * 2024-05-31 2025-06-13 山西高等创新研究院 一种环状核酶系统及其应用
CN118813602B (zh) * 2024-06-21 2025-07-08 毕昇(北京)生物科技有限公司 基于尖孢镰刀菌CoB基因的I型内含子的构建体及其构建方法、RNA环化方法、环状RNA和应用
CN119040364B (zh) * 2024-08-29 2025-06-27 优环(苏州)生物医药科技有限公司 一种基于核酶自剪接的无残留序列环状rna及其制备方法
CN119120509A (zh) * 2024-10-12 2024-12-13 宁波大学 一种大别班达病毒环状rna及其在制备疫苗中的应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2948884A1 (de) 1979-12-05 1981-06-11 Basf Ag, 6700 Ludwigshafen 2-hydroxypropylimidazole, verfahren zu ihrer herstellung und verwendung als oelloesliche korrosionsinhibitoren
US4661450A (en) 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US4664777A (en) 1984-07-30 1987-05-12 Exxon Research And Engineering Company Process for improving octane by the conversion of fused multi-ring aromatics and hydroaromatics to lower molecular weight compounds
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1993014218A1 (en) 1992-01-13 1993-07-22 Duke University Enzymatic rna molecules
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
DK148292D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
US5591737A (en) 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US6096880A (en) 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
CN1136278A (zh) 1993-10-19 1996-11-20 麦克公司 双膦酸盐与生长激素促分泌素的组合
JPH09510212A (ja) 1994-03-11 1997-10-14 メルク エンド カンパニー インコーポレーテッド 肺疾患を処置するための組成物
CA2144940A1 (en) 1994-03-18 1995-09-19 Chikara Murakata Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5656606A (en) 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5747485A (en) 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
GB2308064A (en) 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP0897908A1 (de) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
US6211174B1 (en) 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
US6620597B1 (en) 1998-01-09 2003-09-16 University Of Utah Research Foundation Method for in vitro amplification of circular DNA
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
NZ521488A (en) 2000-03-28 2004-07-30 Univ Queensland A construct capable of release in closed circular form from a larger nucleotide sequence permitting site specific expression and/or developmentally regulated expression of selected genetic sequences
CN1882548A (zh) 2003-10-24 2006-12-20 奥斯佩克斯制药公司 2,6－二异丙基苯酚的pH敏感性前药
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2007044627A2 (en) 2005-10-06 2007-04-19 Sloan Kettering Institute For Cancer Research Compositions and methods for delivery of interfering rna
CN101016264A (zh) 2007-01-22 2007-08-15 西安新安医药科技有限公司 用于治疗的硝基咪唑衍生物、制备方法及用途
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
US8283344B2 (en) 2007-09-10 2012-10-09 Merck & Co., Inc. Method of treating inherited severe neutropenia
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
PL2434891T3 (pl) 2009-05-27 2020-12-28 Ptc Therapeutics, Inc. Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
JP5267874B2 (ja) 2009-07-24 2013-08-21 ソニー株式会社 信号処理装置、及び、信号処理方法
KR20110095439A (ko) 2010-02-19 2011-08-25 건국대학교 산학협력단 암모니움 이미다졸륨 염 및 이를 함유하는 염료감응 태양전지용 전해질 조성물
GB2496898B (en) 2011-11-25 2020-10-28 Petroliam Nasional Berhad Petronas Corrosion inhibition
US9353153B2 (en) 2012-02-09 2016-05-31 Riken Cyclic RNA and protein production method
PT2968440T (pt) 2013-03-15 2019-07-31 Zymeworks Inc Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos
ES2746803T3 (es) 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
EP3017013A4 (en) 2013-05-28 2017-01-25 Yanjie Xu Refrigeration system with dual refrigerants and liquid working fluids
US8805972B1 (en) 2013-06-26 2014-08-12 Kaspersky Lab Zao Multi-platform operational objective configurator for computing devices
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP3193941B1 (en) 2014-08-06 2024-05-22 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
DK3173092T3 (da) * 2015-04-22 2019-08-05 Curevac Ag Rna-holdig sammensætning til behandling af tumorsygdomme
WO2016197121A1 (en) 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
JP6685039B2 (ja) 2015-08-26 2020-04-22 国立大学法人東北大学 化合物、イオン液体、白金族元素の抽出剤、白金族元素の抽出方法
LU92830B1 (en) 2015-09-15 2017-04-03 Luxembourg Inst Of Health Lih Biomarkers for heart failure
CN105176981B (zh) 2015-09-17 2017-03-15 广州永诺健康科技有限公司 用于环状rna表达的dna序列和表达载体及其应用
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
EP3356556B1 (en) 2015-09-29 2019-12-11 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A method for diagnosing a disease by detection of circrna in bodily fluids
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
WO2017118734A1 (en) 2016-01-08 2017-07-13 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
CA3019536A1 (en) 2016-03-31 2017-10-05 Takeda Vaccines, Inc. Live, attenuated alphavirus constructs and methods and uses thereof
EP3458106A4 (en) 2016-05-18 2020-03-18 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
KR20230074598A (ko) 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
SI3458083T1 (sl) 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
US11001861B2 (en) 2016-05-18 2021-05-11 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
AU2017266948B2 (en) 2016-05-18 2024-07-04 Fundacion Para La Investigacion Medica Aplicada Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
JP7210287B2 (ja) 2016-05-18 2023-01-23 モダーナティエックス・インコーポレイテッド Ｉｉ型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド
CA3028682A1 (en) 2016-06-20 2017-12-28 Howard Y. Chang Circular rnas and their use in immunomodulation
US20180010175A1 (en) 2016-09-22 2018-01-11 Bio-Rad Laboratories, Inc. Methods and compositions for cloning circular rna
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US20190290694A1 (en) 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
CN106801050B (zh) 2017-02-20 2020-01-14 广州永诺生物科技有限公司 一种环状rna高通量测序文库的构建方法及其试剂盒
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
DK3596041T3 (da) 2017-03-15 2023-01-23 Modernatx Inc Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
CA3057394A1 (en) 2017-04-14 2018-10-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
WO2018220583A1 (en) 2017-05-31 2018-12-06 Vilnius University Production of cyclic adenylates and their use as allosteric regulators
EP3642342A4 (en) 2017-06-23 2021-03-17 Cornell University RNA MOLECULES, CIRCULAR RNA PRODUCTION METHODS, AND PROCESSING METHODS
KR20200127152A (ko) * 2017-12-15 2020-11-10 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도
KR102806143B1 (ko) 2018-05-01 2025-05-14 프레드 허친슨 캔서 센터 유전자 발현을 위한 나노입자 및 이의 용도
WO2019222275A2 (en) 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
BR112020024292A2 (pt) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
WO2020010242A1 (en) 2018-07-03 2020-01-09 Washington State University Pharmaceutical agents for use in smoking and tobacco cessation
JP2021531829A (ja) 2018-07-24 2021-11-25 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 環状化された遺伝子操作ｒｎａ及び方法
US20220119375A1 (en) 2018-08-17 2022-04-21 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. 3-aryloxy-3-aryl-propylamine compound and uses thereof
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
CA3131319A1 (en) 2019-03-25 2020-10-01 Avak Kahvejian Compositions comprising modified circular polyribonucleotides and uses thereof
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
EP3983539A1 (en) 2019-06-14 2022-04-20 Flagship Pioneering Innovations VI, LLC Circular rnas for cellular therapy
JP7581264B2 (ja) 2019-07-02 2024-11-12 トラスティーズ オブ タフツ カレッジ 細胞および組織への薬剤の送達のための新規ペプチド、組成物および方法
CA3146883A1 (en) 2019-08-28 2021-03-04 Howard Y. Chang Modified circular rnas and methods of use thereof
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
JP7642620B2 (ja) 2019-09-19 2025-03-10 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための頭部基脂質化合物及び組成物
EP3819377A1 (en) 2019-11-08 2021-05-12 Justus-Liebig-Universität Gießen Circular rna and uses thereof for inhibiting rna-binding proteins
WO2021113777A2 (en) 2019-12-04 2021-06-10 Orna Therapeutics, Inc. Circular rna compositions and methods
AU2021237738A1 (en) 2020-03-20 2022-11-10 Orna Therapeutics, Inc. Circular RNA compositions and methods
JP2023525270A (ja) 2020-05-08 2023-06-15 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
BR112022023554A2 (pt) 2020-05-19 2023-04-11 Orna Therapeutics Inc Composições e métodos de rna circular

Also Published As

Publication number Publication date
WO2019236673A1 (en) 2019-12-12
US11981909B2 (en) 2024-05-14
US11203767B2 (en) 2021-12-21
US20240158807A1 (en) 2024-05-16
EP3801639A1 (en) 2021-04-14
AU2023201630A1 (en) 2023-04-13
US11352640B2 (en) 2022-06-07
CA3100276A1 (en) 2019-12-12
BR112020024292A2 (pt) 2021-03-02
US20230050306A1 (en) 2023-02-16
CN118256490A (zh) 2024-06-28
US20220025395A1 (en) 2022-01-27
SG11202011162RA (en) 2020-12-30
CN112399860A (zh) 2021-02-23
AU2019280583B2 (en) 2022-12-15
US20200080106A1 (en) 2020-03-12
US20210403944A1 (en) 2021-12-30
JP2021526792A (ja) 2021-10-11
US11845950B2 (en) 2023-12-19
IL319091A (en) 2025-04-01
JP2024105707A (ja) 2024-08-06
US20210198688A1 (en) 2021-07-01
IL279157A (en) 2021-01-31
KR20210018323A (ko) 2021-02-17
US11352641B2 (en) 2022-06-07
US20210363540A1 (en) 2021-11-25
CN112399860B (zh) 2024-08-16
US11447796B2 (en) 2022-09-20
US20240271158A1 (en) 2024-08-15
AU2019280583A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
MX2020013236A (es) Acido ribonucleico (arn) circular para traduccion en celulas eucariotas.
Zaffagnini et al. Protein S-nitrosylation in photosynthetic organisms: a comprehensive overview with future perspectives
BR112022012921A2 (pt) Métodos para editar de forma alvejada ácido ribonucleico e para tratar a síndrome de usher tipo ii, ácido ribonucleico de recrutamento da adenosina desaminase, construto ou vetor de entrega, célula, e, uso do ácido ribonucleico de recrutamento da adenosina desaminase ou do construto ou vetor de entrega
CO2022014527A2 (es) Método y fármaco para tratar el síndrome de hurler
CY1112323T1 (el) Παραγωγη και καθαρισμος της il-29
CO2018006699A2 (es) Métodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspensión sin suero adecuado para uso clínico
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
JP2016504026A5 (es)
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
WO2014172470A3 (en) Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
PH12020551957A1 (en) Codon-optimized acid alpha-glucosidase expression cassettes and methods of using same
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
JP2019536462A5 (es)
BRPI0612273A2 (pt) anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade
UY40194A (es) Constructo que codifica toxina con actividad plaguicida, composiciones, células que la contienen, así como métodos y usos
JP2016501515A5 (es)
EA201691192A1 (ru) Гены токсинов axmi477, axmi482, axmi486 и axmi525 и способы их применения
CN106257988A (zh) 新颖方法、多肽以及其用途
CL2023001433A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
MX2022005670A (es) Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.
UA122856C2 (uk) Варіантний інсектицидний ген ахмі115 та способи його застосування
Jørgensen et al. An evolutionary preserved intergenic spacer in gadiform mitogenomes generates a long noncoding RNA
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
RU2014129220A (ru) Новый аттенуированный полиовирус: pv-1 mono-cre-x
CN108300738B (zh) 一种nod遗传背景的中性粒细胞缺失的人源化小鼠模型的制备方法